Guinness Ventures announces investment in GlycanAge

18 December 2025

At Guinness Ventures, we are delighted to have participated in GlycanAge’s $8.7m (€7.4m) investment funding round. GlycanAge is a biotechnology company transforming how individuals and healthcare providers understand healthy ageing through advanced glycan analysis.

 

What problem is GlycanAge addressing?

Biological age is one of the most important indicators of long-term health outcomes, yet it has traditionally been difficult to measure in a clinically robust and commercially accessible way. This gap has limited the ability of consumers, clinicians and wellness providers to track the impact of lifestyle, treatment and prevention strategies with real accuracy.

 

How does GlycanAge address this problem?

Founded by Dr Nikolina Lauc and Dr Gordan Lauc, GlycanAge has developed a scientifically validated diagnostic test that measures biological age through the analysis of glycans, a critical component of the immune system. Their platform provides users with actionable insight, enabling more informed health decisions and supporting the growing shift towards personalised, preventative care.

 

Why have we backed GlycanAge?

We believe GlycanAge is exceptionally well positioned in a fast-growing global market. The company combines deep scientific expertise, strong intellectual property and a clear commercial strategy across consumer, corporate wellness and clinical channels. Its leadership team brings significant experience across glycoscience, diagnostics and commercial development, supported by a capable operational and scientific group.

Congratulations to Dr Nikolina Lauc, Dr Gordan Lauc and the entire GlycanAge team. We look forward to supporting you through the next phase of growth.

 

More Information

To find out more about the company, visit GlycanAge.

 

Are you a HealthTech company looking for investment?

To find out more about what Guinness Ventures looks for, click here.